GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Additional Paid-In Capital

Cormedix (STU:19KA) Additional Paid-In Capital : €362.52 Mil(As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Additional Paid-In Capital?


Cormedix's quarterly additional paid-in capital declined from Sep. 2023 (€365.44 Mil) to Dec. 2023 (€359.18 Mil) but then increased from Dec. 2023 (€359.18 Mil) to Mar. 2024 (€362.52 Mil).

Cormedix's annual additional paid-in capital increased from Dec. 2021 (€272.87 Mil) to Dec. 2022 (€311.80 Mil) and increased from Dec. 2022 (€311.80 Mil) to Dec. 2023 (€359.18 Mil).

Cormedix Additional Paid-In Capital Historical Data

The historical data trend for Cormedix's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Additional Paid-In Capital Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 197.05 214.98 272.87 311.80 359.18

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 317.29 319.47 365.44 359.18 362.52

Cormedix Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cormedix Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cormedix's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cormedix (STU:19KA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Additional Paid-In Capital
Comparable Companies
IMRX MACK PSTX ATXS CBUS DNTH GRTS IVVD FATE INZY OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CRMD:USA
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Website
https://www.cormedix.com
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix (STU:19KA) Headlines

No Headlines